Zisook S
J Clin Psychiatry. 1984 Jul;45(7 Pt 2):53-8.
Three double-blind, placebo controlled studies found isocarboxazid (40-50 mg/day) to be efficacious and safe for the treatment of atypical depression. The few instances of liver function elevations were generally borderline; one patient had a marked increase of both SGOT and SGPT (with normal bilirubin and alkaline phosphatase) at Week 6 which normalized over the next several months. Another patient had a mild, temporary hypertensive reaction after eating cheese but did not require any treatment alterations. Drops in both systolic and diastolic blood pressures, as well as orthostatic changes, were common but generally mild and well-tolerated. The most frequently noted side effects were dizziness, headache, dry mouth, insomnia, and constipation. Clinical adverse reactions tended to be mild and to respond to dosage decreases. Isocarboxazid appears to be an underutilized and potentially valuable agent for the treatment of depressed patients.
三项双盲、安慰剂对照研究发现，异卡波肼（40 - 50毫克/天）治疗非典型抑郁症有效且安全。肝功能升高的情况较少，一般处于临界值；一名患者在第6周时血清谷草转氨酶（SGOT）和血清谷丙转氨酶（SGPT）均显著升高（胆红素和碱性磷酸酶正常），在接下来的几个月里恢复正常。另一名患者食用奶酪后出现轻度、短暂的高血压反应，但无需调整治疗方案。收缩压和舒张压下降以及体位性变化较为常见，但一般较轻且耐受性良好。最常出现的副作用是头晕、头痛、口干、失眠和便秘。临床不良反应往往较轻，减少剂量后即可缓解。异卡波肼似乎是一种未得到充分利用但可能有价值的治疗抑郁症患者的药物。
